Class Action Lawsuit Claims Kind Mood+ Patches Do Not Work as Advertised

New to ClassAction.org? Read our Newswire Disclaimer

A proposed class action lawsuit claims that Kind Patches Limited has misled consumers into believing that its Mood+ Patches can provide positive neurological effects, given that the patches do not contain dopamine or a dopamine agonist.

Want to stay in the loop on class action lawsuits that matter to you? Sign up for ClassAction.org’s free weekly newsletter.

The 31-page lawsuit alleges that although Kind Patches Limited markets its Mood+ Patches, formerly called Dopamine Patches, as an effective, holistic transdermal supplement to improve mood, attention, focus and motivation, the patches are “nothing but a sham” since they contain only herbal ingredients that cannot provide the same benefits as the actual dopamine molecule or a dopamine agonist via transdermal delivery.

“In fact, Defendant has admitted on its website, buried in fine print where consumers are not likely to see, that its Dopamine Patches do not contain dopamine,” the complaint reads.

The filing explains that dopamine is a neurotransmitter that is primarily responsible for feelings of pleasure and satisfaction, and affects motivation, concentration and mood. Kind Patches markets its transdermal Mood+ Patches as a way to increase dopamine production and “support mood stability and emotional balance” to “elevate feelings of mental wellness” without pills, powders or “complicated routines,” the case says.

The complaint alleges, however, that the Mood+ Patches do not contain any dopamine, but rather a variety of herbal ingredients— such as mucuna pruriens extract, 5-HTP, lion’s mane mushroom extract, and rhodiola extract—that are ineffective at increasing dopamine production by way of absorption through the skin.

The filing cites a psychiatrist who stated that “[a]lthough limited data suggest some of the ingredients in these products may slightly help mood and cognitive symptoms, there is no strong evidence that they are effective and safe medications for ADHD.”

The lawsuit accuses Kind Patches of capitalizing on increased consumer interest in “biohacks” by targeting health-conscious individuals who may have limited access to healthcare, cannot afford rising prescription drug costs, or have concerns over dangerous side effects from long-term prescription drug use.

According to the suit, Kind Patches uses deceptive advertising to create the impression that its Mood+ Patches are a cost-effective substitute for FDA-approved prescription medications that are frequently used to treat health conditions associated with dopamine deficiency, including rotigotine, a dopamine agonist that can be administered through a transdermal patch, and stimulants like methylphenidate and amphetamine/dextroamphetamine.

By contrast, the case says, there is little scientific evidence to suggest that the herbal blends in the Mood+ Patches can be absorbed through the skin, meaning that even if the patches could improve dopamine production, the delivery method would be ineffective.

Furthermore, the suit says that on February 4, 2026, the United Kingdom’s Advertising Standards Authority (ASA) issued a ruling in which it determined that Kind Patches’ claims that the Mood+ Patches could provide health benefits were “misleading,” and prohibited the brand from making unsubstantiated claims.

Indeed, the ASA found that the “evidence” Kind Patches cited to prove the patches’ efficacy was based on questionable clinical trials that involved individuals being administered the ingredients orally, not through the skin, and in much larger quantities than the patches contained, the lawsuit states.

The case says that the ASA subsequently stated that, “[c]onsidering the evidence in its entirety, we concluded that the claims has [sic] not been substantiated and that ads were misleading.”

Per the lawsuit, Kind Patches knew and intended that its false and misleading claims that the Mood+ Patches contained dopamine would induce consumers to choose the patches over comparable products not advertised as containing dopamine.

The Kind Patches class action lawsuit looks to cover all individuals in the United States who, during the applicable statute of limitations, purchased Kind Mood+ Patches.

 Looking for current class action lawsuits to join? Check out ClassAction.org’s class action lawsuit list.